This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adinoff, A. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Adinoff, A. D.

PEDIATRICS Vol. 104 No. 2 Supplement August 1999, pp. 393-394

Leukotriene Antagonist Therapy
A Drug Interaction Between Zafirlukast and Theophylline

Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ Arch Intern Med. 1998; 158:1713-1715 [Medline]

The first 20% of the full text of this article appears below.

Purpose of the Study The apparent low adverse effect profile of the new drug zafirlukast has made it an attractive choice in the treatment of asthma. This study describes the first case of a potentially serious drug-drug interaction between zafirlukast and theophylline.

Study Population, Methods, and Results A 15-year-old white girl with asthma had been taking theophylline (Slo-bid, Rhone-Poulenc Rorer Pharmaceuticals Inc, Collegeville, PA) (300 mg twice daily), with drug levels of approximately 61 micromol/L (11.0 µg/mL) for several years. Recently, her serum theophylline levels had increased . . . [Full Text of this Article]